166 related articles for article (PubMed ID: 9735415)
1. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Gazitt Y; Rothenberg ML; Hilsenbeck SG; Fey V; Thomas C; Montegomrey W
Int J Oncol; 1998 Oct; 13(4):839-48. PubMed ID: 9735415
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
3. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Ricotti L; Tesei A; De Paola F; Ulivi P; Frassineti GL; Milandri C; Amadori D; Zoli W
Clin Cancer Res; 2003 Feb; 9(2):900-5. PubMed ID: 12576465
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Bonavida B
Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
[TBL] [Abstract][Full Text] [Related]
5. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.
Liu Q; Gazitt Y
Blood; 2003 May; 101(10):4105-14. PubMed ID: 12521996
[TBL] [Abstract][Full Text] [Related]
7. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
9. 2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Gruber J; Geisen F; Sgonc R; Egle A; Villunger A; Boeck G; Konwalinka G; Greil R
Stem Cells; 1996 May; 14(3):351-62. PubMed ID: 8724701
[TBL] [Abstract][Full Text] [Related]
10. Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis.
Kroning R; Lichtenstein A
Leuk Res; 1998 Mar; 22(3):275-86. PubMed ID: 9619919
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
12. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
[TBL] [Abstract][Full Text] [Related]
13. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
[TBL] [Abstract][Full Text] [Related]
14. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M
Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667
[TBL] [Abstract][Full Text] [Related]
15. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Kielb SJ; Shah NL; Rubin MA; Sanda MG
J Urol; 2001 Aug; 166(2):482-7. PubMed ID: 11458051
[TBL] [Abstract][Full Text] [Related]
16. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
17. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells.
Tan G; Heqing L; Jiangbo C; Ming J; Yanhong M; Xianghe L; Hong S; Li G
Int J Cancer; 2002 Jan; 97(2):168-72. PubMed ID: 11774260
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Zhu K; Gerbino E; Beaupre DM; Mackley PA; Muro-Cacho C; Beam C; Hamilton AD; Lichtenheld MG; Kerr WG; Dalton W; Alsina M; Sebti SM
Blood; 2005 Jun; 105(12):4759-66. PubMed ID: 15728126
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.
Park ST; Byun HJ; Kim BR; Dong SM; Park SH; Jang PR; Rho SB
Biochem Biophys Res Commun; 2013 May; 435(1):153-9. PubMed ID: 23628417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
